Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8344319 | 1.00 | RAB9A (0.47) | RAB9ATDP1SIRT1SIRT2KDM4E | |
| Hydrochloric Acid SCHEMBL29501091 | 0.99 | RAB9A (0.47) | RAB9ATDP1SIRT1SIRT2KDM4E | |
| Acetic Acid SCHEMBL30688430 | 0.99 | RAB9A (0.46) | RAB9ATDP1SIRT1SIRT2KDM4E | |
| SCHEMBL29928873 | 0.99 | RAB9A (0.49) | RAB9ATDP1SIRT1SIRT2KDM4E | |
| Hydrochloric Acid SCHEMBL11355182 | 0.98 | RAB9A (0.48) | RAB9ATDP1SIRT1SIRT2KDM4E | |
| SCHEMBL29872228 | 0.94 | SIRT2 (0.48) | RAB9ATDP1SIRT1SIRT2 | |
| SCHEMBL31046113 | 0.94 | RAB9A (0.44) | RAB9ATDP1SIRT1SIRT2KDM4E | |
| SCHEMBL10727549 | 0.93 | SIRT2 (0.50) | RAB9ATDP1SIRT1SIRT2KDM4E | |
| Hydrochloric Acid SCHEMBL380911 | 0.92 | SIRT2 (0.49) | RAB9ATDP1SIRT1SIRT2KDM4E | |
| SCHEMBL4727432 | 0.91 | SIRT2 (0.49) | RAB9ATDP1SIRT1SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4063856-A1 | METHODS AND COMPOSITIONS FOR IN VITRO SCREENING OF PROTEASE INHIBITORS | Universiteit Antwerpen (BE) | 2022-09-28 | — | — | EP | claimed |
| US-12312621-B2 | Reprogramming urokinase into an antibody-recruiting anticancer agent | YALE UNIVERSITY (US) | 2025-05-27 | — | — | US | disclosed |
| US-20250011468-A1 | Procoagulant Antibodies | NOVO NORDISK AS (DK) | 2025-01-09 | — | — | US | disclosed |
| CN-118955719-A | Procoagulant antibodies | 诺和诺德股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240375145-A1 | METHODS OF MAKING OMNIPHOBIC MATERIALS WITH HIERARCHICAL STRUCTURES AND USES THEREOF | MCMASTER UNIVERSITY (CA) | 2024-11-14 | — | — | US | disclosed |
| US-20240343831-A1 | ANTI-TMPRSS2 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS | REGENERON PHARMA (US) | 2024-10-17 | — | — | US | disclosed |
| US-12084512-B2 | Procoagulant antibodies | NOVO NORDISK A/S (DK) | 2024-09-10 | — | — | US | disclosed |
| CN-110248964-B | Procoagulant antibodies | 诺和诺德股份有限公司 | 2024-08-27 | — | — | CN | disclosed |
| US-12065506-B2 | Anti-TMPRSS2 antibodies and antigen-binding fragments | REGENERON PHARMACEUTICALS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| EP-4387826-A1 | METHODS OF MAKING OMNIPHOBIC MATERIALS WITH HIERARCHICAL STRUCTURES AND USES THEREOF | McMaster University (CA) | 2024-06-26 | — | — | EP | disclosed |
| CN-112513096-B | Improved procoagulant antibodies | 诺和诺德股份有限公司 | 2023-08-25 | — | — | CN | disclosed |
| US-20230265216-A1 | ANTI-TMPRSS2 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS | REGENERON PHARMACEUTICALS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11603413-B2 | Anti-TMPRSS2 antibodies and antigen-binding fragments | REGENERON PHARMACEUTICALS, INC. (US) | 2023-03-14 | — | — | US | disclosed |
| US-20230058721-A1 | Procoagulant Antibodies | NOVO NORDISK AS (DK) | 2023-02-23 | — | — | US | disclosed |
| WO-2023019364-A1 | METHODS OF MAKING OMNIPHOBIC MATERIALS WITH HIERARCHICAL STRUCTURES AND USES THEREOF | MCMASTER UNIVERSITY (CA) | 2023-02-23 | — | — | WO | disclosed |
| EP-4103619-A1 | ANTI-TMPRSS2 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS | Regeneron Pharmaceuticals, Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-4063856-A1 | METHODS AND COMPOSITIONS FOR IN VITRO SCREENING OF PROTEASE INHIBITORS | Universiteit Antwerpen (BE) | 2022-09-28 | — | — | EP | disclosed |
| US-20220098283-A1 | ACE2- and TMPRSS2-Targeted Compositions and Methods for Treating COVID-19 | MADDON ADVISORS LLC (US) | 2022-03-31 | — | — | US | disclosed |
| US-20220081489-A9 | ANTI-TMPRSS2 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS | REGENERON PHARMACEUTICALS, INC. | 2022-03-17 | — | — | US | disclosed |
| US-20220056154-A1 | Bispecific Antibody Compositions and Methods for Treating COVID-19 | MADDON ADVISORS LLC (US) | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343831-A1 | ANTI-TMPRSS2 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS | TMPRSS2, TMPRSS4, TMPRSS6 | RAB9A 4259/4885TDP1 1634/4885SIRT1 4331/4885 |
| US-20230265216-A1 | ANTI-TMPRSS2 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS | TMPRSS2, TMPRSS4, TMPRSS15 | RAB9A 4221/4885TDP1 2202/4885SIRT1 3968/4885 |
| US-12065506-B2 | Anti-TMPRSS2 antibodies and antigen-binding fragments | TMPRSS2, TMPRSS4, TMPRSS15 | RAB9A 4221/4885TDP1 2202/4885SIRT1 3968/4885 |
| US-20220081489-A9 | ANTI-TMPRSS2 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS | TMPRSS2, TMPRSS4, TMPRSS15 | RAB9A 4221/4885TDP1 2202/4885SIRT1 3968/4885 |
| US-12312621-B2 | Reprogramming urokinase into an antibody-recruiting anticancer agent | PLAUR, CD47, CD14 | RAB9A 1274/4885TDP1 3949/4885SIRT1 1015/4885 |
| US-11603413-B2 | Anti-TMPRSS2 antibodies and antigen-binding fragments | TMPRSS2, TMPRSS4, TMPRSS15 | RAB9A 4221/4885TDP1 2202/4885SIRT1 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.